Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQX-1125 drug-drug interaction study with a combined oral contraceptive in healthy women
NL-OMON57753Completed
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of AQX-1125 in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS), sponsored by Aquinox Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration of levonorgestrel, ethinyl estradiol, and AQX-1125, Time to maximum observed plasma concentration of levonorgestrel, ethinyl estradiol, and AQX-1125 and 3 more. Started Oct 2017; status: completed.
02
Drugs
AQX-1125
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on NL-OMON57753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57753.